Metrics as of 10/16/2026, 04:34 PM (Berlin time), refresh in progress.
Fennec Pharmaceuticals Stock
Fennec Pharmaceuticals Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Jeffrey S. Hackman
- Employees
- 35
- Market cap
- $353 M
- IPO
- 15/09/2017
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based…
Fennec Pharmaceuticals stock: price history
1D
-2.9%
1W
-6.2%
1M
-4.8%
6M
+47.9%
YTD
+30.5%
1Y
+16.3%
2Y
+116.0%
5Y
+9.3%
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~54% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Fennec Pharmaceuticals
Analyst assessment of Fennec Pharmaceuticals
PRICE TARGET LOW
US$16.00
CONSENSUS
US$16.00
MEDIAN
US$16.00
PRICE TARGET HIGH
US$16.00
0
STRONG BUY
8
BUY
0
HOLD
0
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 09/09/2026
Fennec Pharmaceuticals stock metrics
P/E
-77.37
P/B
8.19
EV/EBITDA
-131.03
RETURN ON EQUITY
4.6%
NET MARGIN
11.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
48.4%
FLOAT SHARES
16,985,830
AVG. DAILY VOLUME (30D)
153,358
Insider transactions (SEC)
Andrade Robert
Cioffi Christiana Marie
Sayad Pierre Sargis
Evans Terry L
Hackman Jeffrey S.
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Fennec Pharmaceuticals stock
What does Fennec Pharmaceuticals do?
Fennec Pharmaceuticals Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Jeffrey S. Hackman, the company employs around 35 people.
The IPO was on 15/09/2017; the stock trades on NASDAQ under the ticker FENC.
What do analysts say about Fennec Pharmaceuticals stock?
8 analysts rate the stock, the consensus is Buy (as of 09/09/2026).
The average price target is US$16.00, ranging from US$16.00 to US$16.00, with a median of US$16.00.
This is an external assessment, not a statement by Market Jury.
When does Fennec Pharmaceuticals report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 54% stronger than usual.
Does Fennec Pharmaceuticals pay a dividend?
No, Fennec Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Fennec Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Fennec Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Fennec Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.